MX2016016742A - Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). - Google Patents
Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).Info
- Publication number
- MX2016016742A MX2016016742A MX2016016742A MX2016016742A MX2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A
- Authority
- MX
- Mexico
- Prior art keywords
- ceramide
- group
- complications
- ceramides
- concentration
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona, entre otras cosas, un método, y uso del mismo, para predecir complicaciones CV tales como IAM, SCA, accidente cerebrovascular y muerte CV determinando la concentración de por lo menos una ceramida del Grupo A y por lo menos una ceramida del Grupo B en una muestra biológica y comparando esas concentraciones con un control. Encontrar una concentración reducida de por lo menos una ceramida del Grupo A y una concentración elevada de por lo menos una ceramida del Grupo B indica que el sujeto tiene un mayor riesgo de desarrollar una o más complicaciones CV. También se proporciona un subconjunto recientemente identificado de moléculas de ceramida, versiones marcadas de las mismas, y kits y composiciones que comprenden las mismas para su uso en la predicción y/o el diagnóstico de complicaciones CV.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012543P | 2014-06-16 | 2014-06-16 | |
| US14/677,595 US9347960B2 (en) | 2014-06-16 | 2015-04-02 | Ceramides and their use in diagnosing CVD |
| PCT/EP2015/063492 WO2015193325A2 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016742A true MX2016016742A (es) | 2017-04-27 |
| MX380642B MX380642B (es) | 2025-03-12 |
Family
ID=54835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016742A MX380642B (es) | 2014-06-16 | 2015-06-16 | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9347960B2 (es) |
| EP (2) | EP3155440B1 (es) |
| JP (1) | JP6774879B2 (es) |
| KR (2) | KR102636885B1 (es) |
| CN (1) | CN106461685B (es) |
| CA (1) | CA2951578A1 (es) |
| MX (1) | MX380642B (es) |
| SA (1) | SA516380503B1 (es) |
| SG (1) | SG11201609621RA (es) |
| WO (1) | WO2015193325A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| WO2016100549A2 (en) * | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| US20200348316A1 (en) * | 2017-11-20 | 2020-11-05 | Zora Biosciences Oy | Methods for prediction and early detection of diabetes |
| CN114062581A (zh) * | 2017-12-14 | 2022-02-18 | 江苏豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| JP2022508322A (ja) * | 2018-12-06 | 2022-01-19 | ゾラ バイオサイエンシーズ オサケ ユキチュア | 心血管イベントに対するバイオマーカー |
| CN112730638B (zh) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | 糖尿病合并心梗代谢标志物、检测试剂及试剂盒 |
| CN112986454A (zh) * | 2021-05-18 | 2021-06-18 | 天津云检医疗器械有限公司 | 急性心肌梗死的血清标志物、试剂盒和用途 |
| CN113495160B (zh) * | 2021-09-07 | 2021-11-19 | 宝枫生物科技（北京）有限公司 | 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用 |
| CA3241153A1 (en) * | 2021-12-17 | 2023-06-22 | Miroslava Cuperlovic-Culf | Diagnostic lipid biomarkers for covid-19 and methods for use thereof |
| CN116500179B (zh) * | 2023-04-21 | 2023-12-26 | 南京品生医疗科技有限公司 | 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统 |
| CN119198939A (zh) * | 2024-08-30 | 2024-12-27 | 北京大学第三医院（北京大学第三临床医学院） | 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012018771A2 (pt) | 2010-01-29 | 2017-06-20 | Metanomics Gmbh | ''método para dianosticar insuficência cardíaca em um sujeito'' |
| DK2385374T4 (en) | 2010-05-05 | 2018-04-30 | Zora Biosciences Oy | LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE |
| WO2011161062A2 (en) * | 2010-06-20 | 2011-12-29 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP2737321B1 (en) | 2011-07-28 | 2017-03-01 | Metanomics GmbH | Means and methods for diagnosing and monitoring heart failure in a subject |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| WO2014060486A1 (en) | 2012-10-18 | 2014-04-24 | Metanomics Gmbh | Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample |
| CN105008931A (zh) | 2013-03-08 | 2015-10-28 | 佐拉生物科学公司 | 非高密度脂蛋白来源的cvd标志物 |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
-
2015
- 2015-04-02 US US14/677,595 patent/US9347960B2/en active Active
- 2015-06-16 EP EP15733650.4A patent/EP3155440B1/en active Active
- 2015-06-16 CA CA2951578A patent/CA2951578A1/en not_active Abandoned
- 2015-06-16 MX MX2016016742A patent/MX380642B/es unknown
- 2015-06-16 KR KR1020177000864A patent/KR102636885B1/ko active Active
- 2015-06-16 SG SG11201609621RA patent/SG11201609621RA/en unknown
- 2015-06-16 WO PCT/EP2015/063492 patent/WO2015193325A2/en active Application Filing
- 2015-06-16 KR KR1020247004744A patent/KR20240023696A/ko active Pending
- 2015-06-16 EP EP22168767.6A patent/EP4089416A1/en active Pending
- 2015-06-16 CN CN201580031908.1A patent/CN106461685B/zh active Active
- 2015-06-16 JP JP2016573763A patent/JP6774879B2/ja active Active
-
2016
- 2016-05-19 US US15/159,650 patent/US10197582B2/en active Active
- 2016-12-15 SA SA516380503A patent/SA516380503B1/ar unknown
-
2018
- 2018-12-12 US US16/218,363 patent/US11474116B2/en active Active
-
2022
- 2022-02-10 US US17/668,927 patent/US11940453B2/en active Active
-
2024
- 2024-02-14 US US18/441,255 patent/US20240183866A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106461685B (zh) | 2021-05-25 |
| US20150362513A1 (en) | 2015-12-17 |
| US20190113531A1 (en) | 2019-04-18 |
| US9347960B2 (en) | 2016-05-24 |
| KR20240023696A (ko) | 2024-02-22 |
| SG11201609621RA (en) | 2017-01-27 |
| JP6774879B2 (ja) | 2020-10-28 |
| US10197582B2 (en) | 2019-02-05 |
| KR102636885B1 (ko) | 2024-02-19 |
| MX380642B (es) | 2025-03-12 |
| EP3155440A2 (en) | 2017-04-19 |
| EP4089416A1 (en) | 2022-11-16 |
| US20240183866A1 (en) | 2024-06-06 |
| KR20170018905A (ko) | 2017-02-20 |
| EP3155440B1 (en) | 2022-04-20 |
| SA516380503B1 (ar) | 2023-03-23 |
| WO2015193325A3 (en) | 2016-02-25 |
| US11940453B2 (en) | 2024-03-26 |
| US20220163547A1 (en) | 2022-05-26 |
| US11474116B2 (en) | 2022-10-18 |
| WO2015193325A2 (en) | 2015-12-23 |
| CA2951578A1 (en) | 2015-12-23 |
| CN106461685A (zh) | 2017-02-22 |
| BR112016028534A2 (pt) | 2017-08-22 |
| US20160266152A1 (en) | 2016-09-15 |
| JP2017519989A (ja) | 2017-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016016742A (es) | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| CL2020003416A1 (es) | Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268) | |
| CO2018000976A2 (es) | Constructos de anticuerpo para cd70 y cd3 | |
| EA201991105A1 (ru) | Методы оценки риска с использованием общей и специфической неклеточной днк | |
| BR112017010406A2 (pt) | processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência | |
| CO2017005773A2 (es) | Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs | |
| MX2016016904A (es) | Analisis de secuencias de acidos nucleicos. | |
| GB2556004A (en) | Markers of stroke and stroke severity | |
| MX2017003790A (es) | Detección de secuencias diana por percepción de nanoporos de sondas sintéticas. | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| BR112016006312A2 (pt) | método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica | |
| BR112016002668A2 (pt) | métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares | |
| EA201990730A1 (ru) | Рнк-биомаркеры для наследственного ангионевротического отека | |
| ES2684758T3 (es) | Procedimiento para diagnosticar fibrosis hepática | |
| BR112022011676A2 (pt) | Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits | |
| BR112016000231A8 (pt) | métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos | |
| EP3759469A4 (en) | CHAIN TEST DEVELOPMENT DIAGNOSIS ANALYSIS | |
| AR106422A1 (es) | Análisis integrado de líquidos de poros para la caracterización potencial de los reservorios | |
| SG10201907690TA (en) | Device and method for detecting target molecules | |
| MX382055B (es) | Nuevo anticuerpo igf - 1r y su uso para el diagnóstico del cáncer. | |
| CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto |